Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Part B Premium Hike To Accommodate Alzheimer’s Drug Costs Is Premature – Sen. Wyden

Executive Summary

Unprecedented increase spotlights how drug costs could drain Medicare, but Senate Finance Committee chair, a prominent pricing critic, urges waiting until Alzheimer’s coverage policy comes out before raising premiums so high. Draft policy is on track for January release, CMS official says.

You may also be interested in...



Aduhelm & Medicare: HHS Reconsideration Of Premium Hike May Ease Blowback On Coverage

Biogen’s Alzheimer’s drug may not cause as much of a financial headache to American seniors as expected, which could dampen criticism of Medicare’s upcoming coverage determination. But questions remain about what exactly HHS will be able to do about Part B premiums.

Woodcock: High Prices Create Problems For Entire Accelerated Approval Program

Acting FDA commissioner suggests a primary reason for outrage over accelerated approvals is the high costs of certain medications despite their unproven clinical benefits, an issue that is outside of the agency’s purview. Health policy experts says FDA shouldn’t be left off the hook that easily.

Aduhelm Price Cut May Help Pave The Way For Medicare National Coverage Determination

With CMS draft decision expected next month on amyloid-clearing antibodies for Alzheimer’s, Biogen slashes Aduhem’s price 50% to $28,200 per year. Move reverses another aspect of the approval that drew criticism, including the expansive label and long horizon for confirmatory data.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS145389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel